Market Overview

Sarpeta Shares Slammed On Possible Reason For Delay In FDA Final Decision On Eteplirsen


Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower by $4 (20 percent) at $17.41. Concerns over the upcoming decision on Eteplirsen has investors exiting the issue in a big way.

The selling from the pre-market session has spilled over into the regular session. After a lower open, it only manged an $0.08 bounce to $19.98 before more sellers piled into the issue. So far, the ensuing decline has taken the issue to $17.05 and is attempting to rebound. That low coincides with a series of four lows in the issue from $16.84 to $17.22 in mid-May.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (SRPT)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Citi Upgrades Oasis Petroleum On $50 Dollar Oil Estimates

This Firm Is Still Selling Texas Instruments On Lofty Valuation, Apple Exposure